Trials / Completed
CompletedNCT02963922
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 396 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide 3.0 mg | Injected subcutaneously (s.c., under the skin) once daily |
| DRUG | Placebo | Injected subcutaneously (s.c., under the skin) once daily |
Timeline
- Start date
- 2017-02-06
- Primary completion
- 2018-09-10
- Completion
- 2018-09-25
- First posted
- 2016-11-15
- Last updated
- 2020-03-30
- Results posted
- 2019-11-27
Locations
54 sites across 7 countries: United States, Canada, Germany, Israel, Italy, Mexico, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02963922. Inclusion in this directory is not an endorsement.